

Ruxolitinib Cream: Phase 2 Data in Vitiligo

Speakers on Today's Webcast

• Hervé Hoppenot Chief Executive Officer Incyte

• John E. Harris, MD, PhD Associate Professor and Vice Chair Department of Dermatology Director Vitiligo Clinic and Research Center University of Massachusetts Medical School

• Jim Lee, MD, PhD Group Vice President, Inflammation and Autoimmunity Incyte

Forward-looking Statements

Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: expectations regarding ruxolitinib cream trial results and implications of those results; expectations to commence and the expected timing of commencement of Phase 3 clinical trials for ruxolitinib cream for vitiligo; our views of the commercial opportunities, including our views of market size and market opportunities, for our drug product candidates, including ruxolitinib cream for vitiligo; and our expectations regarding further clinical development for ruxolitinib cream and the timing of clinical trial results.


These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; assuming approval of ruxolitinib cream for vitiligo or other indications, the acceptance of ruxolitinib cream in the marketplace and the effects of market competition; manufacturing, sales and marketing requirements; and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended March 31, 2019. We disclaim any intent or obligation to update these forward-looking statements.




Inflammation and Autoimmunity Development

Hervé Hoppenot

Incyte has Three Groups within Clinical Development



Capitalizing on our Expertise in Inflammation and Autoimmunity







Department of Dermatology University of Massachusetts Medical School



Targeting JAK signaling as a novel treatment for vitiligo

Twitter: @HarrisVitiligo



Website:

Umassmed.edu/vitiligo



John E. Harris, MD, PhD Associate Professor University of Massachusetts Medical School







Vitiligo

- 1-2% incidence
- 3-6.5 million (US)
- 75-150 million (world)
- 50% onset before age 20
- Disease associations
 - Type 1 diabetes
 - Lupus
 - Hashimoto thyroiditis
 - Pernicious anemia
 - Addison's disease











Vitiligo is not a cosmetic disease

Am Acad Dermatol November 2015

Khaled Ezzedine, MD, PhD,^a Vaneeta Sheth, MD,^b Michelle Rodrigues, MBBS (Hons), FACD,^c Viktoria Eleftheriadou, MD, PhD,^d John E. Harris, MD, PhD,^e Iltefat H. Hamzavi, MD,^f and Amit G. Pandya, MD,^g on behalf of the Vitiligo Working Group Bordeaux, France; Boston and Worcester, Massachusetts; Melbourne, Australia; Nottingbam, United Kingdom; Detroit, Michigan; and Dallas, Texas

The burden of vitiligo: Patient characteristics associated with quality of life

May W. Linthorst Homan, MD,^{a,b} Phyllis I. Spuls, MD, PhD,^b John de Korte, MA, PhD,^b Jan D. Bos, MD, PhD,^b Mirjam A. Sprangers, MA, PhD,^c and J. P. Wietze van der Veen, MD, PhD^{a,b} Amsterdam, The Netherlands

Background: Vitiligo is commonly regarded as a harmless cosmetic skin problem in Western societies, and the importance of treating patients with vitiligo is often underestimated.

Objective: We sought to determine the clinical and sociodemographic variables that adversely affect the quality of life in adult patients with generalized vitiligo so that these variables can be considered in the treatment and care.


Methods: A total of 245 adult patients with generalized vitiligo completed two quality-of-life questionnaires (the Medical Outcomes Study 36-Item Short-form General Health Survey and the Skindex-29). Physicians assessed sociodemographic and clinical characteristics of these patients.

Results: Dark skin type, vitiligo located on the chest, and treatment in the past appeared to have an adverse impact on the psychosocial domains of quality of life. Moreover, itch was reported by 20% of the patients in this study.

Limitations: Psychiatric comorbidity was not evaluated in the analyses.

Conclusion: Generalized vitiligo is a serious skin disorder with an adverse impact on the emotional state, comparable with that of other major skin diseases. (J Am Acad Dermatol 2009;61:411-20.)

Dermatology Life Quality Index (DLQI)



Vitiligo – unmet medical need


- Poor Quality of Life: Similar to psoriasis/eczema
- Willingness to pay for a cure: Greater than eczema
- No FDA-approved medical treatments!
- Current topicals used off-label have significant side effects

Current vitiligo treatments Segmented and Incomplete

- Topical steroids (striae, atrophy)
- Topical calcineurin inhibitors (burning sensation, hyperpigmentation)
- nbUVB phototherapy (time-consuming-3x/wk >1yr, moderately effective)
- Surgical transplantation (for stable disease only, <5% are candidates)
- Depigmentation (for very severe disease only, <1%, worsens vitiligo)

Current treatments have significant limitations and thus have only penetrated a small part of market, likely <20%

My (simple) Treatment Algorithm





Vitiligo – "Severity" Data from 3 vitiligo specialty clinics



58%	<5% BSA
25%	5-10% BSA
11%	>10-25% BSA
5%	>25-50% BSA
2%	>50% BSA
















Vitiligo – "Severity" **Decision Tree**





Phototherapy, a current vitiligo treatment, is reimbursed at a high level



\$24,000 per year



\$42,000 per year

Vitiligo – The Opportunity


- Vitiligo analogous to psoriasis market 30 years ago: topicals, phototherapy, oral immunosuppressant (methotrexate)
- <u>Psoriasis</u> (7.4M in US/125M worldwide) now with effective therapies, \$8B annual market, estimated to be \$21B by 2022; mostly shared by 10-12 drugs
- <u>Vitiligo</u> (3-6M in US/75-150M world) with no effective, FDA-approved medication

ORIGINAL ARTICLE

A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN- γ for Autoreactive CD8⁺ T-Cell Accumulation in the Skin

John E. Harris¹, Tajie H. Harris², Wolfgang Weninger^{3,4}, E. John Wherry⁵, Christopher A. Hunter² and Laurence A. Turka⁶

Journal of Investigative Dermatology advance online publication, 2 February 2012; doi:10.1038/jid.2011.463





A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8⁺ T-Cell Accumulation in the Skin

John E. Harris¹, Tajie H. Harris², Wolfgang Weninger^{3,4}, E. John Wherry⁵, Christopher A. Hunter² and Laurence A. Turka⁶


Journal of Investigative Dermatology advance online publication, 2 February 2012; doi:10.1038/jid.2011.463

- Clinical and histological appearance same as human
- Gene expression in mouse and human identical
- Only mouse model of skin depigmentation (not hair)
- Only reversible model of vitiligo
- Ongoing studies parallel observations in mouse and human
- Has predicted therapies now in clinical trials (JAK)
- Many companies using this model for preclinical testing

Harris, JID 2012 Rashighi, STM 2014 Harris, JAAD 2016

Richmond, JID 2017a Richmond, JID 2017b Strassner, JAAD 2017 Rodrigues, JAAD 2017 Frisoli, JACI 2017 Richmond, STM 2018

Gene expression is similar in mouse and human vitiligo



ORIGINAL ARTICLE

A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN- γ for Autoreactive CD8⁺ T-Cell Accumulation in the Skin

John E. Harris¹, Tajie H. Harris², Wolfgang Weninger^{3,4}, E. John Wherry⁵, Christopher A. Hunter² and Laurence A. Turka⁶

Journal of Investigative Dermatology advance online publication, 2 February 2012; doi:10.1038/jid.2011.463

Science Translational Medicine

RESEARCH ARTICLE



Mehdi Rashighi,¹ Priti Agarwal,¹ Jillian M. Richmond,¹ Tajie H. Harris,²* Karen Dresser,³ Ming-Wan Su,⁴ Youwen Zhou,⁴ April Deng,³ Christopher A. Hunter,² Andrew D. Luster,⁵ John E. Harris^{1†}



RESEARCH ARTICLE

VITILIGO

CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo

Mehdi Rashighi,¹ Priti Agarwal,¹ Jillian M. Richmond,¹ Tajie H. Harris,²* Karen Dresser,³ Ming-Wan Su,⁴ Youwen Zhou,⁴ April Deng,³ Christopher A. Hunter,² Andrew D. Luster,⁵ John E. Harris^{1†}



Emerging Treatments

CXCL9

CXCL10

Harris et al. JID 2012 Rashighi et al. STM 2014 Richmond et al. JID 2017a Richmond, et al. JID 2017b

IFN-γ

IFNγR

Keratinocytes

ST




CXCR3

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)

Am Acad Dermatol VOLUME 74, NUMBER 2

February 2016 370

Baseline Week4 Week8 Week12 Week16 Week20 Week32 Baseline Week20 51% 42 % 16% 0.8 9 0.9% 1.3 % 8.3%




Aclaris Incyte **Pfizer**


RESEARCH LETTER


John E. Harris, MD, PhD,^a Mehdi Rashighi, MD,^a Nhan Nguyen, MD,^b Ali Jabbari, MD, PhD,^b Grace Ulerio, BA,^b Raphael Clynes, MD, PhD,^b Angela M. Christiano, PhD,^{b,c} and Julian Mackay-Wiggan, MD, MS^b






Is there a functional role for keratinocytes? K5-cre/STAT1^{flox}








Richmond, et al. JID 2017



Topical ruxolitinib for vitiligo





Rothstein R, et al. JAAD 2017



Ruxolitinib cream: Phase 2 data in vitiligo

Jim Lee, MD, PhD

Presented at the 24th World Congress of Dermatology June 10–15, 2019; Milan, Italy

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: Results of a 24-Week, Randomized, Double-Blind, Dose-Ranging, Vehicle-Controlled Study

David Rosmarin, MD,¹ Amit G. Pandya, MD,² Mark Lebwohl, MD,³ Pearl Grimes, MD,⁴ Iltefat Hamzavi, MD,⁵ Alice B. Gottlieb, MD, PhD,⁶ Kathleen Butler, MD,⁷ Fiona Kuo, PhD,⁷ Michael D. Howell, PhD,⁷ Kang Sun, PhD,⁷ John E. Harris, MD, PhD⁸

 ¹Tufts Medical Center, Boston, MA, USA; ²University of Southwestern Medical Center, Dallas, TX, USA; ³Mount Sinai Hospital, New York, NY, USA; ⁴The Vitiligo & Pigmentation Institute of Southern California, Los Angeles, CA, USA;
⁵Henry Ford Medical Center, Detroit, MI, USA; ⁶Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁷Incyte Corporation, Wilmington, DE, USA; ⁸University of Massachusetts Medical School, Worcester, MA, USA


Eligibility Criteria and Study Design

Key Inclusion Criteria

- Patients aged 18–75 years with clinical diagnosis of vitiligo
- Depigmented areas including both of the following
 - ≥0.5% of total BSA on the face
 - $\geq 3\%$ of total BSA on nonfacial areas

Key Exclusion Criteria

- Current or recent clinically meaningful infection
- Dermatologic disease besides vitiligo
- Use of biological, investigational, or experimental therapy within 12 weeks of screening
- Use of laser or light-based treatments within 8 weeks of screening
- Use of immunomodulating systemic drugs or topical treatments within 4 weeks of screening
 Prior JAK inhibitor therapy



Patient Demographics and Clinical Characteristics

Demographics and Clinical Characteristics	Total (N=157)		
Age, mean ± SD, years	48.3±12.85		
Male, n (%)	73 (46.5)		
Skin type, n (%)			
l I	6 (3.8)		
Ш	50 (31.8)		
Ш	50 (31.8)		
IV	31 (19.7)		
V	10 (6.4)		
VI	10 (6.4)		


Clinical Characteristics	Total (N=157)		
Baseline F-VASI, mean ± SD	1.26±0.82		
Baseline T-VASI, mean ± SD	17.95±15.46		
Facial BSA, mean ± SD, %	1.48±0.86		
Total BSA, mean ± SD, %	22.05±18.38		
Duration of disease, median (range), years	14.0 (0.3–67.9)		
Diagnosed in childhood, n (%)	35 (22.3)		
Other autoimmune disorders,* n (%)	42 (26.8)		
Prior therapy, n (%)			
Topical corticosteroids	72 (45.9)		
Calcineurin inhibitors	70 (44.6)		
Phototherapy	55 (35.0)		

T-VASI, total Vitiligo Area Scoring Index.

* Including patients (n [%]) with thyroid disorders (39 [24.8]), juvenile diabetes mellitus (2 [1.3]), and pernicious anemia (1 [0.6]).

Primary Efficacy Endpoint: F-VASI50 Response

• At Week 24, the highest F-VASI50 response was achieved with the 1.5% QD and BID regimens




*** P<0.001 vs vehicle at Week 24; ** P<0.01 vs vehicle at Week 24; * P<0.05 vs vehicle at Week 24.

F-VASI75 Response

Incyte

• At Week 24, the highest F-VASI75 response was achieved with the 1.5% BID regimen



Treatment-Emergent Adverse Events Through 24 Weeks

 Ruxolitinib cream was not associated with clinically significant application site reactions or serious treatment-related adverse events

	Vehicle (n=32)	Ruxolitinib Cream				Total
		0.15% QD (n=31)	0.5% QD (n=31)	1.5% QD (n=30)	1.5% BID (n=33)	(n=157)
Patients with TEAE, n (%)	20 (62.5)	20 (64.5)	22 (71.0)	22 (73.3)	20 (60.6)	104 (66.2)
Most common TEAEs,* n (%)						
Acne	1 (3.1)	4 (12.9)	3 (9.7)	3 (10.0)	5 (15.2)	16 (10.2)
Application site pruritus	3 (9.4)	6 (19.4)	3 (9.7)	3 (10.0)	1 (3.0)	16 (10.2)
Pruritus	3 (9.4)	1 (3.2)	4 (12.9)	4 (13.3)	2 (6.1)	14 (8.9)
Viral upper respiratory tract infection	5 (15.6)	3 (9.7)	2 (6.5)	2 (6.7)	1 (3.0)	13 (8.3)
Headache	3 (9.4)	1 (3.2)	0	3 (10.0)	2 (6.1)	9 (5.7)
Treatment-related TEAE, n (%)	12 (37.5)	11 (35.5)	11 (35.5)	10 (33.3)	10 (30.3)	54 (34.4)
TEAE leading to discontinuation, n (%)	1 (3.1)	1 (3.2)†	0	0	0	2 (1.3)
Serious TEAE, n (%)	0	0	0	0	1 (3.0) [‡]	1 (0.6)

TEAE, treatment-emergent adverse event.


* Occurring in ≥5% of the total patient population; † Headache related to treatment; ‡ Subdural hematoma not related to treatment.

Conclusions

- Significantly more patients achieved F-VASI50 after 24 weeks of treatment with ruxolitinib cream (all regimens) vs vehicle
 - F-VASI50 was most notably achieved with ruxolitinib cream 1.5% BID (45.5%) and 1.5% QD (50.0%); both P<0.001 vs vehicle
- F-VASI75 was achieved by 30.3% and 16.7% of patients in the 1.5% BID and 1.5% QD groups, respectively
- All doses of ruxolitinib cream were well tolerated



Next Steps in Ruxolitinib Cream Development





Q&A



Building Value through Innovative Medicines

ir@incyte.com

@incyte